Suppr超能文献

晚期喉癌诱导化疗后行放疗或放化疗时的器官保存及治疗毒性

Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.

作者信息

Guadagnolo Beverly A, Haddad Robert I, Posner Marshall R, Weeks Linda, Wirth Lori J, Norris Charles M, Sullivan Christopher A, Goguen Laura, Busse Paul M, Tishler Roy

机构信息

Joint Center for Radiation Therapy, Boston, MA, USA.

出版信息

Am J Clin Oncol. 2005 Aug;28(4):371-8. doi: 10.1097/01.coc.0000162423.13431.8d.

Abstract

OBJECTIVES

The authors reviewed records of patients with advanced laryngeal cancer treated with induction chemotherapy (IC) and hyperfractionated radiation therapy (RT) or chemoradiation (CRT) to determine the rates of organ preservation and function.

METHODS

A total of 29 patients with stage III (45%) and stage IV (55%) squamous cell carcinoma of the larynx (SCCL), were treated with IC and RT or CRT in 1 of 7 consecutive trials. Fifty-five percent had clinically node-positive disease. Fifty-five percent and 45% had T3 or T4 tumors, respectively. All received 3 cycles of platinum-based IC. Daily RT was given to 48%, twice-daily RT to 45%, and concomitant boost RT to 7%. CRT was carboplatin (28%) or docetaxel (28%). Those treated with twice-daily RT did not receive CRT.

RESULTS

The median follow-up is 52 months. Overall survival is 66%. Relapse occurred in 12 patients (41%), and 6 underwent salvage laryngectomy (5 stage III, 1 stage IV). Fifty-nine percent of patients (17 of 29) are alive at last follow-up with an anatomically intact larynx, and 48% (14 of 29) are alive with a functional larynx. Of the 23 patients for whom detailed information on gastrostomy tube (g-tube) placement/removal was available, median time with g-tube was 12 months, and 15 of 23 patients (65%) had a g-tube for 6 months or more. Twenty-three of all 29 patients (79%) retained an anatomically intact larynx, but 7 of 23 (30%) never resumed their pretreatment organ function. The overall rate of functional organ preservation, regardless of survival, was 55% (16/29). The 7 of 29 patients (26%) who retained a nonfunctional larynx required permanent g-tube or were unable to return to pretreatment oral intake capability. Nine of 13 with T4 SCCL (69%) compared with 7 of 16 (44%) T3 SCCL retained a functional larynx.

CONCLUSION

The rate of larynx preservation is high, but toxicity remains significant with IC followed by hyperfractionated RT or CRT in advanced laryngeal cancer. Half of all patients were alive, able to retain their larynx, and return to pretreatment function. Advanced stage was not an indicator of poor outcome.

摘要

目的

作者回顾了接受诱导化疗(IC)联合超分割放射治疗(RT)或放化疗(CRT)的晚期喉癌患者的记录,以确定器官保留率和功能。

方法

共有29例III期(45%)和IV期(55%)喉鳞状细胞癌(SCCL)患者在连续7项试验中的1项中接受了IC联合RT或CRT治疗。55%的患者临床淋巴结阳性。分别有55%和45%的患者患有T3或T4肿瘤。所有患者均接受了3个周期的铂类IC。48%的患者接受每日一次RT,45%的患者接受每日两次RT,7%的患者接受同步推量RT。CRT采用卡铂(28%)或多西他赛(28%)。接受每日两次RT的患者未接受CRT。

结果

中位随访时间为52个月。总生存率为66%。12例患者(41%)出现复发,6例接受挽救性喉切除术(5例III期,1例IV期)。59%的患者(29例中的17例)在最后一次随访时存活且喉部解剖结构完整,48%(29例中的14例)存活且喉部功能正常。在23例有胃造瘘管(g管)放置/拔除详细信息的患者中,g管留置的中位时间为12个月,23例患者中有15例(65%)g管留置时间为6个月或更长。29例患者中有23例(79%)喉部解剖结构完整,但23例中有7例(30%)从未恢复到治疗前的器官功能。无论生存情况如何,功能性器官保留的总体率为55%(16/29)。29例患者中有7例(26%)保留了无功能的喉部,需要永久性g管或无法恢复到治疗前的经口进食能力。13例T4 SCCL患者中有9例(69%)保留了功能性喉部,而16例T3 SCCL患者中有7例(44%)保留了功能性喉部。

结论

喉保留率较高,但在晚期喉癌中,IC联合超分割RT或CRT后的毒性仍然很大。所有患者中有一半存活,能够保留喉部并恢复到治疗前的功能。晚期并非预后不良的指标。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验